search
Back to results

Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy

Primary Purpose

Type2 Diabetes

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Novolin 30R;Pioglitazone;Metformin
Sponsored by
Qianfoshan Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type2 Diabetes focused on measuring type 2 diabetes, remission, short-term intensive insulin therapy

Eligibility Criteria

18 Years - 78 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Newly diagnosed, insulin-naive type 2 diabetes outpatients
  • Diabetes duration less than 1 year

Exclusion Criteria:

  • Various acute complications
  • Hepatic transaminase >2.5x normal reference value (glutamic-pyruvic transminase>100U/L, glutamic-oxalacetic transaminase > 100U/L)
  • Abnormal renal functions (serum cretinine>the normal reference value)
  • Cardiac insufficiency (America NYHA caediac function >3)
  • Type 1 diabetes mellitus
  • Ongoing hormone therapy
  • Women in gestation and lactation
  • Patients with other endocrine disorders

Sites / Locations

  • Shandong Provincial Hospital
  • Qianfoshan Hospital
  • Qilu Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Novolin 30R;Pioglitazone;Metformin

Arm Description

Drugs: Insulin (Novolin 30R) monotherapy or combined with one or two oral drugs (metformin 0.5 mg tid and pioglitazone hydrochloride 15 mg qd).

Outcomes

Primary Outcome Measures

prolonged-remission rate
hyperglycemia below diagnostic thresholds for diabetes without active pharmacologic therapy or ongoing procedures of 5 years' duration.
partial-remission rate
hyperglycemia below diagnostic thresholds for diabetes without active pharmacologic therapy or ongoing procedures of more than 3 months' duration, and less than 5 years.

Secondary Outcome Measures

Full Information

First Posted
January 2, 2017
Last Updated
January 24, 2017
Sponsor
Qianfoshan Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03030300
Brief Title
Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Qianfoshan Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate the long-term remission rate of short-term intensive insulin (STII) therapy in newly diagnosed type 2 diabetes outpatients and investigate the predictors contributing to the remission rate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type2 Diabetes
Keywords
type 2 diabetes, remission, short-term intensive insulin therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
170 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Novolin 30R;Pioglitazone;Metformin
Arm Type
Experimental
Arm Description
Drugs: Insulin (Novolin 30R) monotherapy or combined with one or two oral drugs (metformin 0.5 mg tid and pioglitazone hydrochloride 15 mg qd).
Intervention Type
Drug
Intervention Name(s)
Novolin 30R;Pioglitazone;Metformin
Intervention Description
Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued; Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin; Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone.
Primary Outcome Measure Information:
Title
prolonged-remission rate
Description
hyperglycemia below diagnostic thresholds for diabetes without active pharmacologic therapy or ongoing procedures of 5 years' duration.
Time Frame
5 years
Title
partial-remission rate
Description
hyperglycemia below diagnostic thresholds for diabetes without active pharmacologic therapy or ongoing procedures of more than 3 months' duration, and less than 5 years.
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
78 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Newly diagnosed, insulin-naive type 2 diabetes outpatients Diabetes duration less than 1 year Exclusion Criteria: Various acute complications Hepatic transaminase >2.5x normal reference value (glutamic-pyruvic transminase>100U/L, glutamic-oxalacetic transaminase > 100U/L) Abnormal renal functions (serum cretinine>the normal reference value) Cardiac insufficiency (America NYHA caediac function >3) Type 1 diabetes mellitus Ongoing hormone therapy Women in gestation and lactation Patients with other endocrine disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lin Liao, MD
Organizational Affiliation
Qianfoshan Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Shandong Provincial Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250001
Country
China
Facility Name
Qianfoshan Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250012
Country
China
Facility Name
Qilu Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250014
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy

We'll reach out to this number within 24 hrs